Tresha Desai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tresha Desai has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Ana Carolina Paschoalini Mafra
Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri
11 shared publications - Andrew Houston
Washington University in St. Louis 4 Saint Louis, MO
11 shared publications - Brian T. Edelson
Department of Pathology and Immunology, Washington University in St. Louis
11 shared publications - Cliff Grant Robinson
Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri
11 shared publications - David G. DeNardo
Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA
11 shared publications - Dhaval P. Bhatt
Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, Missouri
11 shared publications
Latest Publications
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Data from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Despite advances in screening and prevention, cervical cancer remains a leading cause of cancer-related deaths worldwide, underscoring the need for better treatments. In this study, we conducted a multicohort longitudinal study of human cervical tumors and the tumor microenvironment during chemoradiotherapy (CRT) and integrated RNA sequencing and single-cell transcriptomics to define the cellular and molecular programs shaping cell interactions and how CRT alters them. The analysis identified multiple therapeutic targets in CRT-resistant tumors, notably including MDM2, a key mediator of radiation responses in tumor and immune cells. MDM2 inhibition enhanced the effects of radiotherapy in human papillomavirus (HPV)–positive, TP53 wild-type cervical cancer cells; improved radiation response; and reshaped the immune landscape in preclinical models. These findings highlight the potential of combining MDM2 inhibition with CRT to overcome resistance and improve patient outcomes. The insights into therapy-induced changes in tumor and immune compartments could guide improved strategies against treatment-resistant HPV-positive cancers.Significance:Mapping of the impact of chemoradiation on cellular interactions in cervical cancer reveals how treatment reshapes the tumor microenvironment and highlights targets for developing future immunotherapeutic approaches.See related commentary by Klopp, p. 1540
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Despite advances in screening and prevention, cervical cancer remains a leading cause of cancer-related deaths worldwide, underscoring the need for better treatments. In this study, we conducted a multicohort longitudinal study of human cervical tumors and the tumor microenvironment during chemoradiotherapy (CRT) and integrated RNA sequencing and single-cell transcriptomics to define the cellular and molecular programs shaping cell interactions and how CRT alters them. The analysis identified multiple therapeutic targets in CRT-resistant tumors, notably including MDM2, a key mediator of radiation responses in tumor and immune cells. MDM2 inhibition enhanced the effects of radiotherapy in human papillomavirus (HPV)–positive, TP53 wild-type cervical cancer cells; improved radiation response; and reshaped the immune landscape in preclinical models. These findings highlight the potential of combining MDM2 inhibition with CRT to overcome resistance and improve patient outcomes. The insights into therapy-induced changes in tumor and immune compartments could guide improved strategies against treatment-resistant HPV-positive cancers.Significance:Mapping of the impact of chemoradiation on cellular interactions in cervical cancer reveals how treatment reshapes the tumor microenvironment and highlights targets for developing future immunotherapeutic approaches.See related commentary by Klopp, p. 1540
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Singe-cell expression matrix for custom clustering annotation related to Figure 2A
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Singe-cell expression matrix for custom clustering annotation related to Figure 2A
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Top 5 gene ontology pathways enriched in each cell type upon chemoradiation related to Figure 3D
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Top 5 gene ontology pathways enriched in each cell type upon chemoradiation related to Figure 3D
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Supporting material for Figure 5
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Supporting material for Figure 5
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Supporting material for Figure 4
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Supporting material for Figure 4
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Supporting material for Figure 2
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Supporting material for Figure 2
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Supporting material for Figure 3
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Supporting material for Figure 3
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Cytoscape node information related to Fig. 1l
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Cytoscape node information related to Fig. 1l
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Supporting material for Figure 1
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer
Supporting material for Figure 1